BioCryst Pharma (BCRX) Target Raised to $8 at JMP

August 28, 2013 9:34 AM EDT Send to a Friend
Get Alerts BCRX Hot Sheet
Price: $10.68 --0%

Rating Summary:
    12 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 26 | New: 30
Trade BCRX Now!
Join SI Premium – FREE
JMP Securities maintained a Market Outperform rating on BioCryst Pharma (NASDAQ: BCRX) and raised its price target to $8.00 (from $5.00). Analyst Liisa Bayko thinks the company could attract takeover interest from Established firms such as Shire and ViroPharma if upcoming Phase 2a proof of concept data from BCX4161 shows signs of efficacy.

In Liisa's view, the oral kallikrein program is a "potential game changer" in Hereditary Angioedema attacks, and companies seeking to increase focus on rare diseases might be interested.

For an analyst ratings summary and ratings history on BioCryst Pharma (NASDAQ: BCRX) click here. For more ratings news on BioCryst Pharma click here.

Shares of BioCryst Pharma closed at $6.44 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

JMP Securities

Add Your Comment